anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: We conducted a systematic review and meta-analysis to evaluate the clinical effectiveness and safety of riluzole to treat neurodegenerative dyskinesia in patients, using the Cochrane collaboration guidelines.
METHODS: We searched databases including Medline, Embase, and Cochrane without any language filters. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used as a guideline, and the study protocol was registered in PROSPERO (CRD42022354627).
RESULTS: Eleven studies involving 1376 patients were included. There was a significant overall effect of riluzole on changes in motor function scores. However, the level of heterogeneity was I2 = 74%. In the subgroup analyses, there were no significant effects of riluzole on motor scores in hereditary ataxia, Parkinson's disease, or Huntington's disease. In the sensitivity analysis, there were no significant effects of riluzole on motor function scores. Furthermore, there were no significant differences in adverse events between the riluzole and placebo groups.
CONCLUSIONS: Although riluzole may not have significant efficacy for improving motor function in neurodegenerative dyskinesia syndromes compared with placebo, it seems to have an acceptable safety profile. Moreover, it may be effective for hereditary ataxia syndromes, although there was a relatively small effect size and limited quality of evidence.
The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also generally relates to pharmaceutical compositions comprising one or more active pharmaceutical ingredients, such as azelastine or pharmaceutically acceptable salts or esters thereof including azelastine hydrochloride, particularly wherein the compositions are provided in unit dosage form. In certain embodiments, the invention provides such unit dosage pharmaceutical compositions comprising azelastine hydrochloride formulated for use as nasal sprays and/or ocular solutions or drops. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of a variety of allergic and non-allergic conditions, particularly conjunctivitis, sinusitis, rhinitis and rhinosinusitis. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance.
On the first day of neonates' admission to the clinic, their skin condition will be evaluated using the NSCS, and the hydration of skin will be measured using a digital moisture meter with the recommended usage guide. During morning care at 09:00 a.m., almond oil (10 ml) will be applied to their entire body, except for the head. Three hours after the application, at 12:00 a.m., their skin condition will be assessed, and the hydration will be measured and recorded. This application will continue for 5 days.
The purpose of this preliminary study is to test the hypothesis that administration of minocycline to humans with moderate and severe TBI is both safe and feasible in the acute post-injury setting, and to characterize its disposition and effects on biomarkers of traumatic CNS injury in a Phase IIa trial. The data collected will serve as the basis for a larger Phase IIb clinical trial in a randomized placebo-controlled parallel group design, to investigate further its potential safety and efficacy as a therapeutic agent for severe human TBI.

Tetracycline derivatives, including doxycycline and minocycline, have been shown to be neuroprotective when given after traumatic brain injury (TBI) and ischemia in rodents. In particular, reduced lesion volume and improved neurological outcome have been demonstrated following minocycline treatment of TBI. The proposed mechanism for these observations is multifactorial, and includes inhibition of microglial activation, caspase-mediated apoptosis, and the excitotoxic N-methyl-D-aspartic acid (NMDA) pathway. Because comparable inflammatory, excitotoxic and apoptotic pathways have also been implicated in human TBI, we hypothesize that administration of minocycline will confer neuroprotection after moderate to severe TBI in that milieu as well, with the potential for significant clinical benefit. Minocycline is highly lipophilic, and thus penetrates the human central nervous system (CNS). In addition, it has been shown to be safe when used in non-traumatic human neurological disorders.
The invention is aimed at creation of a cosmetic product, which is convenient and simple to use and to prepare, and has high cosmetic properties and daily individual selection of parameters. The said technical result is achieved by that the antistress cosmetic product for daily skin care comprises a body of three composite parts and a filler placed in it in the form of two non-mixed systems. In one of the systems the filler is an ice sample produced by fluid freezing, in another one the filler is a microsample of rock from a mineral banded biotite amphibole plagioclase gneiss. In the upper part of the body cavity there is a reservoir of spherical shape with volume of 47 ml, made of fluoroplastic to locate the filler therein in the form of a fluid for formation of cosmetic ice, in the middle part of the body cavity there is a light impermeable partition with a fixed cone-shaped fixator of the filler made of fluoroplastic and located inside the spherical reservoir. Inside the fixator, there are active elements in the form of rock microsample and crystalline resonator, and inside the cavity of the middle part there are solid-state sources of electromagnetic wave emission with the range of 700, 550, 470, 400 nm, a controller of the system for control of sensor readings collection and processing, with subsequent control of emission modes and a power element with a switch. In the cavity of the lower part of the body there is a metering optoelectronic sensor for express analysis of functional skin condition prior to application.
1363506 Penicillins ASTRA LAKEMEDEL AB 15 Sept 1971 [17 Sept 1970 20 Nov 1970] 43090/71 Heading C2A The invention comprises compounds of structural Formula I and pharmaceutically acceptable acid addition salts thereof,; wherein R is an alkyl group containing two to seven carbon atoms; a radical of Formula II wherein R<SP>2</SP> is H or OH and R<SP>3</SP> is H or halogen; or a radical of formula  and wherein R<SP>1</SP> represents a group of formula where R<SP>4</SP> represents an alkyl group containing 1 to 4 carbon atoms and R<SP>5</SP> represents hydrogen, methyl or ethyl. A process for preparing compounds of Formula I comprises reacting compounds of Formula VIII  wherein A is amino, substituted amino or a group which is convertible into an amino group and R<SP>11</SP> represents hydrogen or a cation with a compound of formula X-R<SP>1</SP> wherein X represents halogen or a functionally equivalent group to give a compound of Formula IX if necessary the group A is converted to' amino and, if desired, the free base is converted to a salt by reaction with a pharmaceutically acceptable acid. An alternative process for preparing compounds of Formula I comprises reacting compounds of formula with compounds of Formula XI to give compounds of Formula IX, in which formula -CO-Y<SP>1</SP> and X<SP>1</SP>-NH- represent groups which react together to form a -CONH- linkage; if necessary the group A is converted into an amino group and, if desired, the free base is converted to a salt by reaction with a pharmaceutically acceptable acid. The compounds of Formula IX wherein A is azido have been prepared by the abovementioned alternative process. The preparation and use as intermediates of compounds of structural Formula XI where X<SP>1</SP> is H are described. Pharmaceutical preparations comprise, as an active ingredient at least one compound of Formula I or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier. A method for the treatment of infectious diseases in animals other than man comprises administering to a host suffering from such a disease a therapeutically acceptable amount of a compound of Formula I or Formula IX where A is azido, or pharmaceutically acceptable salts thereof.
A shampoo leaf comprises a sheet of paper of high wet strength, suitably a vegetable parchment paper, which carries on one or both faces a surface coating of one or more ammonium salts of sulphated fatty alcohols containing 10-18 carbon atoms which adheres to the paper without flaking off, the leaf being such that it can be rubbed on to a user's head without the paper disintegrating.  The detergent, which is preferably derived from lauryl alcohol or from narrow-cut alcohols obtained from coconut or palm kernel oils, usually contains 0.5-1.5% (by weight of the final dried surface coating) of a binder such as a natural gum, for example gum acacia, karaya or tragacanth, or a synthetic hydrophilic colloid, for example an alginate, polyvinyl alcohol, carboxymethylcellulose, methyl or ethyl cellulose, or hydroxymethyl- or hydroxyethyl-cellulose, which helps the detergent to adhere to the paper.  A humectant such as glycerol, ethylene glycol, or diethylene glycol may also be incorporated. Preferably, the leaf has a hole towards one end so that a finger may be inserted to give a grip during use.  In a modification, two sheets, each coated on both sides, are stuck together, each sheet having perforations out of register with those of the other sheet, the perforations serving to allow the passage of detergent from between the sheets during use.  The leaves may be made by passing a web of paper through a bath of concentrated detergent solution, removing excess liquid by squeezing rollers, drying the coated paper by passage through a tunnel-type infra-red drying chamber, and cutting the dry coated paper so obtained into suitably sized pieces.
On the basis of nutrition and exercise management and guidance, Qigong is exercised. Offline intensive learning once a week, 45-60 minutes each time, study for 12 weeks, and arrange online theory lecture once a week. In addition to concentrated learning, subjects in this group were required to practice themselves at home, at least once a day, each time for 30 minutes.
Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
The expression of tsRNA in white adipose tissue (WAT) of VD deficiency male mice with obesity has not been reported. The healthy male C57BL/6J mice aged 4-6 weeks were divided into 4 groups according to the VD3 and fat energy supplement in daily diets. The qPCR verification further demonstrated that tRF5-20-HisGTG-3 were significantly up-regulated and mt-tRF3a-ProTGG was significantly down-regulated not only in HFVDD vs HFVDS, but aslo in HFVDD vs ConVDS. tRF5-22-CysGCA-27 were significantly up-regulated and mt-5'tiRNA-32-SerTGA, mt-5'tiRNA-33-SerTGA and mt-5'tiRNA-33-AlaTGC was significantly down-regulated only in HFVDD vs ConVDS. Enrichment analysis of the qPCR verified DE tsRNAs showed that the 3 up-regulated tsRNAs seemed to be associated with FoxO signaling pathway, GnRH secretion, 2-Oxocarboxylic acid metabolism, Autophagy-animal, Glucagon and insulin signaling pathway, while 4 down-regulated tsRNA seemed to be associated with cell communication, primary metabolic process, metabolic process, response to stimulus, multicellular organismal process, cellular metabolic process, cellular process and biological regulation. The tsRNAs were differentially expressed in VD deficiency with obesity, especially tRF5-20-HisGTG-3, tRF5-22-CysGCA-27, tRF3a-GlyGCC-1, mt-5'tiRNA-33-AlaTGC, mt-5'tiRNA-33-SerTGA, mt-5'tiRNA-32-SerTGA and mt-tRF3a-ProTGG. These tsRNAs seemed to be associated with FoxO signaling pathway, GnRH secretion, 2-oxocarboxylic acid metabolism, autophagy, glucagon and insulin signaling pathway, metabolic process and biological regulation.
Placebo group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to placebo group will be initiated on an inactive placebo pill.
The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Midazolam-ratiopharm®, Midazolam-hameln®).
The present invention relates to the technical field of medicine, particularly to the external preparation of T alpha 1, which is the new purpose of thymosin alpha 1 (T alpha 1) for preparing medicine for treating burns or scalds. The T alpha 1 is polypeptide with an immune function. Currently, the T alpha 1 is clinically regarded as an immunopotentiator for the adjuvant therapy of virus hepatitis, malignant tumors and immune deficiency disorder. The present invention uses the T alpha 1 for treating skin burns and scalds. The T alpha 1 can effectively promote the growth and the healing of wound surfaces of the burns and the scalds by the animal experiment of pharmacodynamics. Therefore, the present invention can be used for preparing the medicine for treating the burns and the scalds.
BACKGROUND: Although surgery is the gold standard following a hip fracture, the potential for rehabilitation and survival rates are low in frail older patients. Some patients may derive more benefit from palliative care. The objectives of this review were to identify the available strategies to improve end-of-life decision-making and palliative care for frail patients with hip fractures and to synthetise their level of support.
METHODS: We conducted a scoping review of the scientific and grey literature, searching seven databases and websites of associations. We included all study designs, expert opinion articles and clinical practice guidelines (CPGs). Data were synthetised according to the Approach to Patient with Limited Life Expectancy and Hip Fracture framework. The number of research items and their level of evidence were tabulated for each of the recommended strategies.
RESULTS: Of the 10 591 items identified, 34 were eligible. The majority of included articles were original research studies (n = 15). Half of the articles and CPGs focused on intervention categories (55%) such as goals of care discussion and comfort care, followed by factors to consider in the end-of-life decision-making process (25%) and prognosis assessments (20%), mainly through the estimation of life expectancy. The level of evidence for these strategies remains low, given the limited number of prospective studies supporting them.
CONCLUSIONS: This scoping review highlighted that end-of-life care in frail older patients with a hip fracture remains understudied. The strategies identified could be prioritised for future research to improve the well-being of the target population while promoting sustainable resource management.
A therapeutic composition is provided that comprises a cell-free conditioned medium containing mixed secretion products of isolated angiogenic progenitor cells obtained from bone marrow, peripheral blood, or adipose tissue. The composition may additionally contain angiogenesis-promoting proteins obtained by transfecting the progenitors cells in culture with an angiogenesis promoting transgene. The composition is useful to promote angiogenesis when introduced into or adjacent to an ischemic site in a patient, such as in myocardium or peripheral limb. Methods are also provided for utilizing such cell-free conditioned medium to deliver angiogenesis-promoting proteins to a patient. The cell-free conditioned medium can also be injected into the blood stream for delivery to the ischemic tissue. The cells can derive from either an autologous or allogenic source and can be lyophilized or frozen for storage.
and the pharmaceutically acceptable salts thereof wherein the variables A, n, R5, R21-R24 and Q are defined herein. These compounds bind VLA-4. Certain of these compound also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. ® KIPO & WIPO 2008
The invention discloses a compound preparation with the function of assisting in preventing and treating mental depression of children and teenagers. Clinical comparative tests show that the composite preparation has good effect of reducing the HAMD score of the depression of children and teenagers. And pharmacological tests of a depression model mouse show that the improved compound preparation obviously shortens the immobility time of tail suspension of the mouse and the immobility time of forced swimming of the mouse, and shows good anti-depression efficacy. And a comparative test shows that the compound preparation provided by the invention is obviously superior to a single probiotic component or mineral component and a medicine-food dual-purpose component thereof. The components supplement each other, the synergy is realized, and multiple target points play a role in treatment. And has the advantages of safety, effectiveness and no toxic or side effect.
PURPOSE:To obtain a cosmetic having refreshing feeling, giving durable make-up and suitable for make-up, by compounding a freon which is liquid at normal temperature. CONSTITUTION:A freon which is liquid at normal temperature (e.g. trichloromonofluoromethane, trichlorotrifluoroethane, etc.) is compounded to a cosmetic at an amount of 0.5-70%. Since freon has high safety to skin and extremely high rate of evaporation, it is suitable as a component of make-up cosmetic. It can be stored over a long period without causing degradation of the quality because freon is noncorrosive to polymeric compounds and metals. Freon can be dissolved at an arbitrary ratio in a low-boiling hydrocarbon or cyclic or linear dimethylpolysiloxane having low polymerization degree and used as a volatile oily component of a cosmetic. The rate of evaporation of the cosmetic can be controlled by mixing the cosmetic with a freon.
Cancer cell dormancy is a reversible process whereby cancer cells enter a quiescent state characterized by cell cycle arrest, inhibition of cell migration and invasion, and increased chemoresistance. Because of its reversibility and resistance to treatment, dormancy is a key process to study, monitor, and interfere with, in order to prevent tumor recurrence and metastasis and improve the prognosis of cancer patients. However, to achieve this goal, further studies are needed to elucidate the mechanisms underlying this complex and dynamic dual process. Here, we review the contribution of extracellular vesicles (EVs) to the regulation of cancer cell dormancy/awakening, focusing on the cross-talk between tumor and non-tumor cells in both the primary tumor and the (pre-)metastatic niche. Although EVs are recognized as key players in tumor progression and metastasis, as well as in tumor diagnostics and therapeutics, their role specifically in dormancy induction/escape is still largely elusive. We report on the most recent and promising results on this topic, focusing on the EV-associated nucleic acids involved. We highlight how EV studies could greatly contribute to the identification of dormancy signaling pathways and a dormancy/early awakening signature for the development of successful diagnostic/prognostic and therapeutic approaches.
TG5 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 120 hours after EVL .
ETHNOPHARMACOLOGICAL RELEVANCE: Ischemia-reperfusion (IR) injury can result in acute renal failure. Oxidative stress is a major factor in IR-induced cell death in the kidneys. According to traditional Chinese medicine, earthworms (Pheretima aspergillum) can be used to treat various kidney diseases.
AIM OF THE STUDY: The present study was designed to understand the protective effects of the water extract of earthworms (WEE) against oxidative stress on the kidneys and the crucial molecular events associated with its nephroprotective activity.
MATERIALS AND METHODS: Cytotoxicity caused by H2O2 in HEK293, HK2, and primary mouse renal tubular epithelial cells (TECs) was used to investigate the effect of WEE on oxidative stress-induced renal injury in vitro. IR-induced kidney injury was established using rats as an in vivo model. The WEE-mediated protection of the kidneys against oxidative stress was compared with that of glutathione, a common antioxidant used as a positive control.
RESULTS: In HEK293 cells, HK2 cells, and primary mouse TECs, WEE relieved H2O2-induced mitochondrial damage, apoptosis, and ferroptosis. In kidney cells, WEE increased the expression of Sirt1, boosted LKB1 and AMPK phosphorylation, and upregulated nuclear Nrf2. Suppression of Sirt1 and LKB1 knock down abrogated WEE-induced protection against H2O2. WEE ameliorated IR-induced kidney injury and intrarenal inflammation in rats. In rat kidneys, WEE mitigated mitochondrial damage and suppressed IR-induced apoptosis and ferroptosis. Mechanistically, WEE increased Sirt1 expression, enhanced the phosphorylation of LKB1 and AMPK, and increased intranuclear Nrf2 levels in IR kidneys. IR treatment resulted in considerable increase in renal MDA levels and a prominent decrease in antioxidative enzyme activity. These lesions were significantly alleviated by WEE.
CONCLUSIONS: WEE mitigated H2O2-induced cytotoxicity in kidney cells in vitro and improved IR-induced kidney damage in rats. Mechanistically, WEE potentiated the Sirt1/Nrf2 axis and relieved mitochondrial damage in the kidney cells. These events inhibited the apoptosis and ferroptosis induced by oxidative stress. Our findings support the potential application of WEE for the clinical treatment of kidney diseases caused by intrarenal oxidative stress.